SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
___________________
Date of Report (Date of earliest event reported) August 12, 1997
BIOCONTROL TECHNOLOGY, INC.
(Exact name of registrant as specified in its charter)
Pennsylvania 0-10822 25-1229323
(State of other jurisdiction (Commission File Number) (IRS Employer
of incorporation) Identification No.)
300 Indian Springs Road, Indiana, Pennsylvania 15701
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (412) 349-1811
_________________________________________________________________
(Former name or former address,
if changes since last report.)
Item 1. Change in Control of Registrant.
Not applicable.
Item 2. Acquisition or Disposition of Assets.
Not applicable.
Item 3. Bankruptcy or Receivership.
Not applicable.
Item 4. Changes in Registrant's Certifying Accountant
Not applicable.
Item 5. Other Events.
On August 12, 1997, Biocontrol Technology, Inc.
(NASDAQ:BICO) announced that it is preparing to submit a 510(k)
Notification to the Food and Drug Administration for marketing
approval for its Diasensor 1000 noninvasive glucose sensor for
diabetics.
Item 6. Resignation of Registrant's Directors.
Not Applicable
Item 7. Financial Statement, Pro Forma Financial Information
and Exhibits.
(a) Financial Statements and Businesses Acquired - Not
Applicable.
(b) Pro Forma Financial Information - Not Applicable.
(c) Exhibits-Press Release
SIGNATURES
Pursuant to the requirement of the Securities Exchange Act
of 1934, the Registrant has duly caused this Report to be signed
on its behalf by the undersigned hereunto duly authorized.
BIOCONTROL TECHNOLOGY, INC.
by /s/ Fred E. Cooper
Fred E. Cooper, CEO
DATED: August 12, 1997
BICO
BIOCONTROL TECHNOLOGY, INC
2275 Swallow Hill Road, Building 2500
Pittsburgh, PA 15220
Press Release
Release: Immediate
For More Information, Call:
Investors Media
Diane McQuaide
Susan Taylor
1.412.429.0673
1.412.279.9455 phone
1.412.279.9690 fax
1.412.279.9447 fax
BIOCONTROL PREPARING FDA SUBMISSION
Pittsburgh, PA - August 12, 1997 - Biocontrol Technology,
Inc. (Nasdaq:BICO) announced today that it is preparing to submit
a 510(k) Notification to the Food and Drug Administration for
marketing approval for its Diasensor 1000 noninvasive glucose
sensor for diabetics.
"Although there can be no guarantees, we hope to submit the
510(k) in the very near future," said Fred E. Cooper, chief
executive officer. "In addition, we expect to soon commence
marketing the Diasensor 1000 in the Far East. We are reviewing
which city to open up first and once that is decided, we will
start taking orders."
Using near-infrared technology, the Diasensor 1000 measures
glucose levels in blood without the need to finger prick.
Biocontrol Technology, Inc. has its corporate offices in
Pittsburgh, PA and is involved in the development and manufacture
of biomedical devices and environmental products.
